Literature DB >> 33371186

zzm321990 Candida lusitaniae Breakthrough Fungemia in an Immuno-Compromised Adolescent: Case Report and Review of the Literature.

Athanasia Apsemidou1, Miriam Antonie Füller2, Evgeny A Idelevich3,4, Oliver Kurzai5,6, Athanasios Tragiannidis1,2, Andreas H Groll2.   

Abstract

Candida lusitaniae is a rare cause of candidemia that is known for its unique capability to rapidly acquire resistance to amphotericin B. We report the case of an adolescent with grade IV graft-vs.-host disease after hematopoietic cell transplantation who developed catheter-associated C. lusitaniae candidemia while on therapeutic doses of liposomal amphotericin B. We review the epidemiology of C. lusitaniae bloodstream infections in adult and pediatric patients, the development of resistance, and its role in breakthrough candidemia. Appropriate species identification, in vitro susceptibility testing, and source control are pivotal to optimal management of C. lusitaniae candidemia. Initial antifungal therapy may consist of an echinocandin and be guided by in vitro susceptibility and clinical response.

Entities:  

Keywords:  Candida lusitaniae; breakthrough; candidemia; infection; resistance; transplantation

Year:  2020        PMID: 33371186      PMCID: PMC7766689          DOI: 10.3390/jof6040380

Source DB:  PubMed          Journal:  J Fungi (Basel)        ISSN: 2309-608X


  30 in total

Review 1.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

2.  Breakthrough candidemia after the introduction of broad spectrum antifungal agents: A 5-year retrospective study.

Authors:  Giovanni L Breda; Felipe F Tuon; Jacques F Meis; Patricia F Herkert; Ferry Hagen; Letícia Z de Oliveira; Viviane de Carvalho Dias; Clóvis Arns da Cunha; Flávio Queiroz-Telles
Journal:  Med Mycol       Date:  2018-06-01       Impact factor: 4.076

3.  Acquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy.

Authors:  Sandra A Asner; Stefano Giulieri; Manuel Diezi; Oscar Marchetti; Dominique Sanglard
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

4.  Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods.

Authors:  Erika J Ernst; Keiko Yodoi; Ellen E Roling; Michael E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

5.  Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.

Authors:  David R Andes; Nasia Safdar; John W Baddley; Geoffrey Playford; Annette C Reboli; John H Rex; Jack D Sobel; Peter G Pappas; Bart Jan Kullberg
Journal:  Clin Infect Dis       Date:  2012-03-12       Impact factor: 9.079

6.  Candida lusitaniae: a cause of breakthrough fungemia in cancer patients.

Authors:  A Minari; R Hachem; I Raad
Journal:  Clin Infect Dis       Date:  2000-12-28       Impact factor: 9.079

Review 7.  Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology.

Authors:  Oliver A Cornely; Martin Hoenigl; Cornelia Lass-Flörl; Sharon C-A Chen; Dimitrios P Kontoyiannis; C Orla Morrissey; George R Thompson
Journal:  Mycoses       Date:  2019-07-19       Impact factor: 4.377

8.  Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome.

Authors:  Bradley J Atkinson; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Med Mycol       Date:  2008-09       Impact factor: 4.076

Review 9.  Breakthrough invasive fungal infections: Who is at risk?

Authors:  Jeffrey D Jenks; Oliver A Cornely; Sharon C-A Chen; George R Thompson; Martin Hoenigl
Journal:  Mycoses       Date:  2020-09-04       Impact factor: 4.377

10.  Comparative Genomics for the Elucidation of Multidrug Resistance in Candida lusitaniae.

Authors:  Abhilash Kannan; Sandra A Asner; Emilie Trachsel; Steve Kelly; Josie Parker; Dominique Sanglard
Journal:  mBio       Date:  2019-12-24       Impact factor: 7.867

View more
  3 in total

Review 1.  Candida lusitaniae: Biology, Pathogenicity, Virulence Factors, Diagnosis, and Treatment.

Authors:  Manuela Gómez-Gaviria; Héctor M Mora-Montes; Diana F Mendoza-Reyes
Journal:  Infect Drug Resist       Date:  2022-08-31       Impact factor: 4.177

Review 2.  Diagnosis and Treatment of Invasive Candidiasis.

Authors:  Natalia Barantsevich; Elena Barantsevich
Journal:  Antibiotics (Basel)       Date:  2022-05-26

3.  Healthcare-Associated Laboratory-Confirmed Bloodstream Infections-Species Diversity and Resistance Mechanisms, a Four-Year Retrospective Laboratory-Based Study in the South of Poland.

Authors:  Agnieszka Chmielarczyk; Monika Pomorska-Wesołowska; Dorota Romaniszyn; Jadwiga Wójkowska-Mach
Journal:  Int J Environ Res Public Health       Date:  2021-03-09       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.